|
Enveric Biosciences, a Naples-headquartered biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.
The USPTO issues a notice of allowance after making the determination that a patent should be granted from an application.
The application titled, “N-Hetercycle Substituted Tryptamine Derivatives and Methods of Using,” contains composition of matter and method of use claims for a family of tryptamine derivatives. The allowed claims cover a novel subset of “multi-substituent” tryptamine derivative compounds and also their use to treat brain disorders.
“This notice of allowance is particularly exciting as the allowed claims cover Enveric’s lead candidate, EB-003, which is currently in preclinical development to support an IND application,” said Joseph Tucker, director and CEO of Enveric.
Dr. Tucker continued, “EB-003 is intended to target major undertreated mental health indications, including treatment-resistant depression and anxiety. Preclinical testing has shown its potential to promote neuroplasticity without inducing the hallmark hallucinations associated with most psychedelic and psychedelic-inspired molecules.” He added, “EB-003 also potentially offers the opportunity to administer treatment without requiring a healthcare professional to be present during treatment, which would be a paradigm shift compared to first-generation psychedelics.”
The USPTO has granted Enveric a broad range of composition of matter claims for tryptamine derivatives in 12 US patents. Enveric also has 34 national applications pending in the US and other countries, and 2 Patent Cooperation Treaty patent applications pending in pursuit of broad national and international patent protection for its key compounds in target countries.
Enveric’s lead molecule, EB-003, is intended to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity and without also inducing hallucinations in the patient. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing all other novel, patented Psybrary drug candidates to third-party licensees advancing non-competitive market strategies for patient care.
|